For many parents and babies, this past winter was a rough time as an early flu season combined with RSV (respiratory syncytial virus) and COVID-19 to create a “tripledemic” of infectious respiratory illnesses.
This coming winter could spell relief from infant RSV.
This week, the FDA approved a monoclonal antibody treatment to protect infants and young babies against RSV, which the American Academy of Pediatrics says results in the hospitalization of approximately 1 to 3% of children under 12 months of age every year.
